Kevin Gorman, Neurocrine CEO
October 5, 2023 11:14 AM EDT
R&D

Neu­ro­crine re­ports a sec­ond PhI­II suc­cess in con­gen­i­tal adren­al hy­per­pla­sia, this time in chil­dren

Lei Lei Wu

News Reporter

Neu­ro­crine Bio­sciences said its treat­ment for con­gen­i­tal adren­al hy­per­pla­sia (CAH) — a ge­net­ic dis­or­der that caus­es hor­mone im­bal­ance — helped re­duce the dai­ly dose of steroids that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

For­mer FDA chief calls job cuts ‘hap­haz­ard, poor­ly thought-out’

NIH pay­ment cuts are 'rea­soned and ra­tio­nal,' gov­ern­ment says

No­vo looks to re­coup $830M from hy­per­ten­sion drug part­ner, claim­ing fraud

Af­ter re­search piv­ot, Bio­gen beefs up pipeline with Stoke's late-stage Dravet can­di­date

Trump blog: Unions aim to halt fed­er­al lay­offs in court hear­ing

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times